Previous studies had confirmed that PD-L1 is expressed in 20% of subgroup of triple-negative breast cancers, and the overexpression of PD-L1 associated with large tumor size, high grade, poor survival, and highly proliferative properties as well as chemo- and radiotherapy resistance [15–17]. Here, CD274 is linked to triple-negative breast carcinoma.